Literature DB >> 28521686

Prothymosin Alpha: An Alarmin and More...

Pinelopi Samara1, Chrysoula-Evangelia Karachaliou2, Kyriaki Ioannou1, Nikos E Papaioannou1, Ioannis F Voutsas3, Christos Zikos2, Ioannis Pirmettis2, Minas Papadopoulos2, Hubert Kalbacher4, Evangelia Livaniou2, Ourania E Tsitsilonis1, Wolfgang Voelter4.   

Abstract

BACKGROUND/
OBJECTIVE: Prothymosin alpha (proTα) is a ubiquitous polypeptide first isolated by Haritos in 1984, whose role still remains partly elusive. We know that proTα acts both, intracellularly, as an anti-apoptotic and proliferation mediator, and extracellularly, as a biologic response modifier mediating immune responses similarly to molecules termed as "alarmins". Our research team pioneered the elucidation of the mechanisms underlying the observed activities of proTα.
RESULTS: We were the first to demonstrate that proTα levels increase during normal and abnormal cell proliferation. We showed that proTα acts pleiotropically, inducing immunomodulatory effects on immune cell populations. We revealed that the immunoreactive region of proTα is the carboxyterminal decapeptide proTα(100-109) and both molecules stimulate innate immune responses, signaling through Toll-like receptors (TLRs), specifically TLR-4. We reported that proTα and proTα(100-109) bind on the surface of human neutrophils on sites involving TLR-4, and cell activation is complemented by cytoplasmic calcium ion influx. Further, we showed that proTα and proTα(100-109) act as adjuvants upstream of lymphocyte stimulation and, in the presence of antigen, promote the expansion of antigen-reactive effectors. Most recently, we reported that proTα(100-109) may accumulate in experimentally inflamed sites and can serve as a surrogate biomarker in severe bacterial infections, proposing that extracellular release of proTα or proTα(100- 109) alerts the immune system during conditions of danger.
CONCLUSION: We, therefore, suggest that proTα, and likely proTα(100-109), act as alarmins, being important immune mediators as well as biomarkers, and could eventually become targets for new therapeutic/diagnostic approaches in immune-related diseases like cancer, inflammation, and sepsis. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Prothymosin alpha; alarmin; cancer; inflammation; proTα(100-109); sepsis

Mesh:

Substances:

Year:  2017        PMID: 28521686     DOI: 10.2174/0929867324666170518110033

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  11 in total

1.  Involvement of SNARE Protein Interaction for Non-classical Release of DAMPs/Alarmins Proteins, Prothymosin Alpha and S100A13.

Authors:  Hayato Matsunaga; Sebok Kumar Halder; Hiroshi Ueda
Journal:  Cell Mol Neurobiol       Date:  2020-08-27       Impact factor: 5.046

2.  Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma.

Authors:  Andrea M Patterson; Shuhong Zhang; Liqiong Liu; Hongge Li; Pratibha Singh; Yunlong Liu; Sherif S Farag; Louis M Pelus
Journal:  Stem Cell Rev Rep       Date:  2021-09-12       Impact factor: 5.739

3.  Prothymosin Alpha: A Novel Contributor to Estradiol Receptor Alpha-Mediated CD8+ T-Cell Pathogenic Responses and Recognition of Type 1 Collagen in Rheumatic Heart Valve Disease.

Authors:  Livia S A Passos; Prabhash K Jha; Dakota Becker-Greene; Mark C Blaser; Dayanna Romero; Adrien Lupieri; Galina K Sukhova; Peter Libby; Sasha A Singh; Walderez O Dutra; Masanori Aikawa; Robert A Levine; Maria C P Nunes; Elena Aikawa
Journal:  Circulation       Date:  2022-02-14       Impact factor: 29.690

Review 4.  Cell Senescence and Central Regulators of Immune Response.

Authors:  Sergey M Lunin; Elena G Novoselova; Olga V Glushkova; Svetlana B Parfenyuk; Tatyana V Novoselova; Maxim O Khrenov
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

5.  Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis.

Authors:  Anurag Kumar; Vikas Kumar; Mohit Arora; Manish Kumar; Prajwal Ammalli; Bhaskar Thakur; Jitender Prasad; Sarita Kumari; Mehar Chand Sharma; Shashank Sharad Kale; Shyam S Chauhan
Journal:  Biosci Rep       Date:  2022-04-29       Impact factor: 3.976

6.  Identification of prothymosin alpha (PTMA) as a biomarker for esophageal squamous cell carcinoma (ESCC) by label-free quantitative proteomics and Quantitative Dot Blot (QDB).

Authors:  Yanping Zhu; Xiaoying Qi; Cuicui Yu; Shoujun Yu; Chao Zhang; Yuan Zhang; Xiuxiu Liu; Yuxue Xu; Chunhua Yang; Wenguo Jiang; Geng Tian; Xuri Li; Jonas Bergquist; Jiandi Zhang; Lei Wang; Jia Mi
Journal:  Clin Proteomics       Date:  2019-04-05       Impact factor: 3.988

Review 7.  Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application.

Authors:  Martina Severa; Jing Zhang; Elena Giacomini; Fabiana Rizzo; Marilena Paola Etna; Melania Cruciani; Enrico Garaci; Michael Chopp; Eliana Marina Coccia
Journal:  Mult Scler Relat Disord       Date:  2018-10-02       Impact factor: 4.339

8.  Development of a specific IgY-based ELISA for prothymosin alpha, a bioactive polypeptide with diagnostic and therapeutic potential.

Authors:  Chrysoula-Evangelia Karachaliou; Ioannis V Kostopoulos; Vyronia Vassilakopoulou; Persefoni Klimentzou; Maria Paravatou-Petsotas; Wolfgang Voelter; Hubert Kalbacher; Christos Zikos; Ourania Tsitsilonis; Evangelia Livaniou
Journal:  Heliyon       Date:  2019-11-01

9.  A Novel Classifier Based on Urinary Proteomics for Distinguishing Between Benign and Malignant Ovarian Tumors.

Authors:  Maowei Ni; Jie Zhou; Zhihui Zhu; Jingtao Yuan; Wangang Gong; Jianqing Zhu; Zhiguo Zheng; Huajun Zhao
Journal:  Front Cell Dev Biol       Date:  2021-08-30

10.  Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide.

Authors:  Anastasios I Birmpilis; Chrysoula-Evangelia Karachaliou; Pinelopi Samara; Kyriaki Ioannou; Platon Selemenakis; Ioannis V Kostopoulos; Nadia Kavrochorianou; Hubert Kalbacher; Evangelia Livaniou; Sylva Haralambous; Athanasios Kotsinas; Farzin Farzaneh; Ioannis P Trougakos; Wolfgang Voelter; Meletios-Athanasios Dimopoulos; Aristotelis Bamias; Ourania Tsitsilonis
Journal:  Cancers (Basel)       Date:  2019-11-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.